Activiomics

Under the technology agreement Activiomics will use its mass spectrometry-based TIQUAS platform to gain insight into the signaling mechanisms of therapeutic antibodies in relevant cell-based systems.

The company, called Activiomics, last week announced a collaboration with GlaxoSmithKline that will use its TIQUAS technology to analyze novel inflammatory pathways by identifying biomarkers and validating targets.

Pages

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.